Clinical trials: Injury of Body Region
Burn Injury, Burns
Foreign-National Burn Patients in a Border-Region Burn Center
This retrospective cohort study will evaluate burn patients hospitalized and treated at the Burn Center of Gaziantep City Hospital between October 2023 and June 2026.
- Trial name
- NCT07673796
- Volunteers
- 1,400 people
- Sponsor
- Gaziantep City Hospital
Burn Injury, In-Hospital Mortality
Burn Mortality Prediction Scores
This retrospective observational cohort study evaluates hospitalized burn admissions treated at the Burn Center of Gaziantep City Hospital between October 2023 and February 2026.
- Trial name
- BURN-PRED (NCT07689890)
- Testing
- Retrospective Prognostic Score Assessment
- Where
- Turkey (Türkiye)
- Volunteers
- 1,082 people
- Sponsor
- Gaziantep City Hospital
Melanoma, Sarcoma
Pilot Study of a Double Isolation Perfusion Schedule Using Melphalan Alone for Intransit Melanoma or Unresectable Sarcoma of the Extremity
Hyperthermic isolated limb perfusion with melphalan alone is administered as a double perfusion schedule. These two isolates limb perfusions with melphalan are treated 3-6 weeks apart.
- Trial name
- NCT00001577
- Testing
- double isolated limb perfusion with melphalan alone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Liver Neoplasms, Neoplasm Metastasis
A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) With Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver
Patients with unresectable primary or metastatic cancer confined to the liver will undergo a 1 hour hyperthermic isolated hepatic perfusion (IHP) via the portal vein and hepatic artery with escalating dose melphalan.
- Trial name
- NCT00001587
- Testing
- Isolated hepatic portal and arterial perfusion, Melphalan
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Burn Body Region Unspecified, Burn Shock
Enteral Resuscitation Nepal
Nepal and the South Asian sub-continent carry some of the highest rates of burn injury globally, with associated high morbidity and mortality.
- Trial name
- NCT05559489
- Testing
- Oral Rehydration Solution, Lactated Ringer
- Where
- Nepal
- Volunteers
- 240 people
- Sponsor
- Nepal Health Research Council
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Colorectal Neoplasm, Liver Neoplasm
A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver
Patients with unresectable metastatic colorectal cancer confined to the liver will undergo a 1 hour hyperthermic isolated hepatic perfusion (IHP) with escalating dose melphalan.
- Conditions
- Colorectal Neoplasm, Liver Neoplasm, Neoplasm Metastasis
- Trial name
- NCT00001576
- Testing
- Melphalan, Floxuridine, Leucovorin
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)